Familial Hypercholesterolemia News and Research

RSS
LDL apheresis can reduce cholesterol levels in patients with familial hypercholesterolemia

LDL apheresis can reduce cholesterol levels in patients with familial hypercholesterolemia

Genetic testing strategy for familial high cholesterol questioned

Genetic testing strategy for familial high cholesterol questioned

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

Lomitapide shows promise in treating homozygous familial hypercholesterolemia

University of Cambridge forms new spin-out company to supply hIPSC-derived cells

University of Cambridge forms new spin-out company to supply hIPSC-derived cells

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

FDA accepts NDA filing for KYNAMRO to treat HoFH

FDA accepts NDA filing for KYNAMRO to treat HoFH

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Positive results from Sanofi and Regeneron’s SAR236553/REGN727 Phase 2 trial on heFH

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

New cholesterol lowering drugs on the horizon

New cholesterol lowering drugs on the horizon

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Karo Bio initiates patient recruitment in eprotirome phase III trial for HeFH

Karo Bio initiates patient recruitment in eprotirome phase III trial for HeFH

Karo Bio receives approval to initiate eprotirome phase III study in HeFH

Karo Bio receives approval to initiate eprotirome phase III study in HeFH

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia

Alkem, Karo Bio partner to license eprotirome

Alkem, Karo Bio partner to license eprotirome

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Study sheds light on novel functions of certain PCSK enzymes

Study sheds light on novel functions of certain PCSK enzymes